DARWIN-EU is a project that aims to establish a sustainable platform for generating and using real-world evidence (RWE) to support decision-making in healthcare across Europe. The project brings together a consortium of academic institutions, patient organizations, regulatory authorities, and industry partners to build a comprehensive RWE ecosystem that supports the development, regulation, and reimbursement of innovative healthcare products and services.
The DARWIN-EU project focuses on several key areas of RWE, including data collection, data quality and management, data analytics and interpretation, and data sharing and dissemination. The project aims to address the current gaps in RWE infrastructure in Europe and to facilitate the integration of RWE into decision-making processes across the healthcare sector.
One of the key objectives of DARWIN-EU is to establish a European Health Data Space (EHDS) that enables secure and standardized sharing of health data across Europe. The EHDS will support the collection of RWE from a variety of sources, including electronic health records, claims data, patient registries, and clinical trials. The data collected through the EHDS will be analyzed using advanced analytics tools to generate insights into healthcare outcomes, patient populations, and treatment effectiveness.
Another objective of DARWIN-EU is to develop new methods and tools for analyzing and interpreting RWE. This includes the development of machine learning algorithms, natural language processing tools, and other advanced analytics techniques to help identify patterns and insights in large datasets. The project also aims to develop new methods for integrating RWE with other sources of healthcare data, such as genomic data and patient-reported outcomes.
Overall, DARWIN-EU is an important initiative in the context of RWE because it seeks to establish a sustainable infrastructure for collecting, analyzing, and using RWE to support decision-making in healthcare. The project has the potential to generate valuable insights into healthcare outcomes, patient populations, and treatment effectiveness, and to inform the development and regulation of innovative healthcare products and services.
Share this story...
Real World Evidence (RWE) 101 – Data Tokenization
RWE 101 - 4 Potential Uses for Improving Drug Development Real world evidence (RWE) refers to data collected outside the context of traditional clinical trials, such as [...]
Real World Evidence (RWE) 101 – Primary Data versus Secondary Data
RWE 101 - Primary Data versus Secondary Data Primary data and secondary data are two types of data used in research. The main difference between the two [...]
RWE 101 – Secondary Use of Existing Data
RWE 101 - Secondary Use of Existing Data Secondary use of existing data refers to the practice of analyzing data that was collected for a different purpose [...]
RWE 101 – Why is there so much excitement about the use of AI in the context of real world evidence?
RWE 101 - Why is there so much excitement about the use of AI in the context of real world evidence? The use of Artificial Intelligence (AI) [...]
RWE 101 – What is the Difference Between an IRB and a REC?
RWE 101 - What is the Difference Between an IRB and a REC? An Institutional Review Board (IRB) and a Research Ethics Committee (REC) are two different [...]
RWE 101 – Do I Need IRB Approval for My Observational Study?
RWE 101 - Do I Need IRB Approval for My Observational Study? In general, observational studies that involve human subjects require Institutional Review Board (IRB) approval to [...]







